You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Original research
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: March 2020 to March 2026

AbstractFullPdf
Mar 2020384384147
Apr 202020820875
May 2020949441
Jun 202011611649
Jul 2020707223
Aug 2020838347
Sep 202013613632
Oct 202011511537
Nov 2020858622
Dec 2020848437
Jan 202110910968
Feb 202111611630
Mar 202122522565
Apr 202118518567
May 202118818849
Jun 202116716739
Jul 202115815867
Aug 202112712728
Sep 202112812847
Oct 202114614762
Nov 202126526674
Dec 202113913832
Jan 202215716330
Feb 202213614232
Mar 202216416954
Apr 202220120843
May 202220220840
Jun 202218119138
Jul 202216517235
Aug 202216116352
Sep 202217619153
Oct 202210110332
Nov 202213113539
Dec 202213714026
Jan 2023858520
Feb 202313813822
Mar 202314514639
Apr 202310410422
May 202312212224
Jun 202313613631
Jul 202310010330
Aug 202310310330
Sep 2023525219
Oct 2023464610
Nov 202365657
Dec 2023515127
Jan 2024515231
Feb 2024787824
Mar 20248184157
Apr 2024747634
May 2024585824
Jun 2024706926
Jul 2024798021
Aug 2024676418
Sep 2024646630
Oct 2024666638
Nov 2024858723
Dec 2024565634
Jan 202520220288
Feb 2025717135
Mar 2025666627
Apr 2025949425
May 2025707129
Jun 2025676735
Jul 2025110
Aug 2025110
Mar 2026110
Total778978782592